Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ.

Cancer Discov. 2019 Aug 15. doi: 10.1158/2159-8290.CD-19-0582. [Epub ahead of print]

PMID:
31416802
2.

SETD1A protects from senescence through regulation of the mitotic gene expression program.

Tajima K, Matsuda S, Yae T, Drapkin BJ, Morris R, Boukhali M, Niederhoffer K, Comaills V, Dubash T, Nieman L, Guo H, Magnus NKC, Dyson N, Shioda T, Haas W, Haber DA, Maheswaran S.

Nat Commun. 2019 Jun 28;10(1):2854. doi: 10.1038/s41467-019-10786-w.

3.

Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.

Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM.

Cell. 2019 Jun 13;177(7):1903-1914.e14. doi: 10.1016/j.cell.2019.04.004. Epub 2019 Apr 25.

PMID:
31031007
4.

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.

Drapkin BJ, Farago AF.

Trends Pharmacol Sci. 2019 May;40(5):295-297. doi: 10.1016/j.tips.2019.03.005. Epub 2019 Apr 8.

PMID:
30975441
5.

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L.

Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.

PMID:
30362375
6.

Clustered incidence of adult acute promyelocytic leukemia.

Brunner AM, Kim PG, Sadrzadeh H, Drapkin BJ, Sprague KA, Sloan JM, Chai-Ho W, Bhargava P, Pozdnyakova O, Fathi AT.

Leuk Res. 2018 Nov;74:47-50. doi: 10.1016/j.leukres.2018.09.008. Epub 2018 Sep 19. No abstract available.

PMID:
30292128
7.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, Licausi JA, Gomez-Caraballo M, Kem M, Jani KN, Azimi R, Abedpour N, Menon R, Lakis S, Heist RS, Büttner R, Haas S, Sequist LV, Shaw AT, Wong KK, Hata AN, Toner M, Maheswaran S, Haber DA, Peifer M, Dyson N, Thomas RK, Farago AF.

Cancer Discov. 2018 May;8(5):600-615. doi: 10.1158/2159-8290.CD-17-0935. Epub 2018 Feb 26.

8.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV.

JCO Precis Oncol. 2017;1. doi: 10.1200/PO.17.00123. Epub 2017 Nov 7. No abstract available.

9.

Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.

Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT.

Cancer. 2013 Jul 15;119(14):2620-9. doi: 10.1002/cncr.28106. Epub 2013 Apr 26.

10.

Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.

Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Neuberg DS, Fathi AT.

Am J Hematol. 2013 Aug;88(8):642-6. doi: 10.1002/ajh.23462. Epub 2013 May 30.

11.

Analysis of the mitotic exit control system using locked levels of stable mitotic cyclin.

Drapkin BJ, Lu Y, Procko AL, Timney BL, Cross FR.

Mol Syst Biol. 2009;5:328. doi: 10.1038/msb.2009.78. Epub 2009 Nov 17.

12.

Cyclin and cyclin-dependent kinase substrate requirements for preventing rereplication reveal the need for concomitant activation and inhibition.

Ikui AE, Archambault V, Drapkin BJ, Campbell V, Cross FR.

Genetics. 2007 Mar;175(3):1011-22. Epub 2006 Dec 28.

13.

Disruption of mechanisms that prevent rereplication triggers a DNA damage response.

Archambault V, Ikui AE, Drapkin BJ, Cross FR.

Mol Cell Biol. 2005 Aug;25(15):6707-21.

14.

Targeted proteomic study of the cyclin-Cdk module.

Archambault V, Chang EJ, Drapkin BJ, Cross FR, Chait BT, Rout MP.

Mol Cell. 2004 Jun 18;14(6):699-711.

Supplemental Content

Loading ...
Support Center